Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.404 5-jähriger Impact-Faktor: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2015013607
pages 153-172

CD8+ T Cell−Independent Immune-Mediated Mechanisms of Anti-Tumor Activity

G Elizabeth Pluhar
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN. 55108
Christopher A. Pennell
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN. 55445
Michael R. Olin
Department of Pediatrics, School of Medicine, University of Minnesota, Minneapolis, MN 55445

ABSTRAKT

Despite the growing number of preclinical and clinical trials focused on immunotherapy for the treatment of malignant gliomas, the prognosis for this disease remains grim. Cancer immunotherapy seeks to recruit an effective immune response to eliminate tumor cells. To date, cancer vaccines have shown only limited effectiveness because of our incomplete understanding of the necessary effector cells and mechanisms that yield efficient tumor clearance. CD8+ T cell cytotoxic activity has long been proposed as the primary effector function necessary for tumor regression. However, there is increasing evidence that indicates that components of the immune system other than CD8+ T cells play important roles in tumor eradication and control. The following review should provide an understanding of the mechanisms involved in an effective antitumor response to guide future therapeutic designs. The information provided suggests an alternate means of effective tumor clearance in malignant glioma to the canonical CD8+ cytotoxic T cell mechanism.


Articles with similar content:

Tolerance and Cancer: A Critical Issue in Tumor Immunology
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 5-6
Hyam I. Levitsky, Eduardo M. Sotomayor, Ivan Borrello
Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination
Critical Reviews™ in Immunology, Vol.34, 2014, issue 6
I. Jolanda M. de Vries, Jasper J. P. van Beek, Annette E. Skold, Stanleyson V. Hato, Florian Wimmers
Immunogenicity of Dendritic-Tumor Fusion Hybrids and Their Utility in Cancer Immunotherapy
Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Rongxiu Zheng, Peter A. Cohen, Suyu Shu, Walter T. Lee
Therapeutic Dendritic Cell−Based Cancer Vaccines: The State of the Art
Critical Reviews™ in Immunology, Vol.33, 2013, issue 6
Marius M. Strioga, Valerijus Ostapenko, Daniel J. Powell Jr., Neringa T. Dobrovolskiene, Virgil E. J. C. Schijns, Thomas Felzmann, Jaroslav Michalek, Miroslava Matuskova
The Role of Invariant NKT Cells in Allogeneic Hematopoietic Stem Cell Transplantation
Critical Reviews™ in Immunology, Vol.32, 2012, issue 2
Aristeidis Chaidos, Anastasios Karadimitris